GARTNER, an American consultancy, has a simple yet elegant way of describing the life of a promising new technology. First, it is talked up to a peak of inflated expectations. Then it falls into a trough of disillusionment. After that, if it survives, it begins climbing the slope of enlightenment. Finally, it reaches the plateau of productivity. In the world of biotechnology CRISPR/Cas9 (see article), is still ascending towards peak expectations. True to the Gartner hype-cycle, though, an earlie...
GARTNER, an American consultancy, has a simple yet elegant way of describing the life of a promising new technology. First, it is talked up to a peak of inflated expectations. Then it falls into a trough of disillusionment. After that, if it survives, it begins climbing the slope of enlightenment. Finally, it reaches the plateau of productivity. In the world of biotechnology CRISPR/Cas9 (see article), is still ascending towards peak expectations. True to the Gartner hype-cycle, though, an earlie...
Share this Article
Recommended